DYN
Dyne Therapeutics Inc
NASDAQ: DYN · HEALTHCARE · BIOTECHNOLOGY
$25.73
+2.51% today
Updated 2026-07-30
Market cap
$3.88B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.11
Dividend yield
—
52W range
$9 – $25
Volume
2.3M
WallStSmart proprietary scores
37
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D6.7
Valuation
B3/9
Piotroski F-Score
Weak
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$39.20
+52.35%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy12 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 0.93 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-145.14M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-165.24M | $-235.94M | $-317.42M | $-446.21M | $-120.85M |
| EPS | — | — | — | — | $-3.11 |
| Free cash flow | $-156.71M | $-188.89M | $-294.75M | $-405.13M | $-145.14M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Dyne Therapeutics Inc trades at $25.73. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 0.93, it sits in the distress.
Frequently asked questions
What is Dyne Therapeutics Inc's stock price?
Dyne Therapeutics Inc (DYN) trades at $25.73.
Is Dyne Therapeutics Inc overvalued?
Dyne Therapeutics Inc carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Dyne Therapeutics Inc (DYN)?
The 12-month analyst consensus target is $39.20, about 52.4% above the current $25.73. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Dyne Therapeutics Inc's Altman Z-Score is 0.93, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-58.90%
Beta1.06
50D MA$19.70
200D MA$18.55
Shares out0.17B
Float0.16B
Short ratio—
Avg volume2.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—